利塞膦酸盐在降低已确诊骨质疏松症的绝经后妇女髋部骨折风险中的作用。
Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.
作者信息
Gates Brian J, Das Shyamal
机构信息
Clinical Associate Professor, Washington State University College of Pharmacy, PO Box 1495, Spokane WA.
出版信息
Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:1-14. doi: 10.4137/CMAMD.S4092. Epub 2012 Jan 5.
UNLABELLED
Osteoporosis is a significant concern for postmenopausal women and is a critical factor in hip fracture. Examining evidence for osteoporosis medications in hip fracture is important for optimizing treatment.
PURPOSE
Review risedronate's role for hip fracture in postmenopausal women.
METHODS
A literature search was conducted using Medline and Web of Science. The search was limited using the terms "risedronate" and "hip fracture," and to studies that included women. Similar articles linked to the search and pertinent articles in bibliographies were also examined.
RESULTS
Risedronate has demonstrated efficacy and cost effectiveness for hip fracture, but may not be beneficial for patients with low fracture risk. Risedronate is generally well tolerated, but may cause side effects in some patient populations.
CONCLUSION
Risedronate has benefit for hip fracture, but patients should be carefully screened to determine the appropriateness of risedronate before starting treatment.
未标注
骨质疏松症是绝经后女性的一个重大问题，也是髋部骨折的一个关键因素。研究髋部骨折中骨质疏松症药物的证据对于优化治疗很重要。
目的
综述利塞膦酸盐在绝经后女性髋部骨折中的作用。
方法
使用Medline和科学网进行文献检索。检索词限定为“利塞膦酸盐”和“髋部骨折”，并仅限于纳入女性的研究。还检查了与检索相关的类似文章以及参考文献中的相关文章。
结果
利塞膦酸盐已证明对髋部骨折有效且具有成本效益，但对骨折风险低的患者可能无益处。利塞膦酸盐一般耐受性良好，但在某些患者群体中可能会引起副作用。
结论
利塞膦酸盐对髋部骨折有益，但在开始治疗前应仔细筛查患者以确定利塞膦酸盐的适用性。
Zotero 插件